Related Experiment Video
Updated: Dec 22, 2025

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
Published on: June 27, 2020
The nuclear oncoprotein Fra-1: a transcription factor knocking on therapeutic applications' door
Francesco Talotta1,2, Laura Casalino1, Pasquale Verde3
1Institute of Genetics and Biophysics "Adriano Buzzati Traverso" CNR, Naples, Italy.
Abstract:
Among the FOS-related members of the AP-1 dimeric complex, the transcription factor Fra-1, encoded by FOSL1, is crucially involved in human tumor progression and metastasis, thus representing a promising therapeutic target. Here we review the state of the art and discuss the emerging topics and perspectives on FOSL1 and its gene product. First, we summarize the present knowledge on the FOSL1 transcriptional and epigenetic controls, driving Fra-1 accumulation in a variety of human solid tumors. We also present a model on the regulatory interactions between Fra-1, p53, and miRNAs. Then, we outline the multiple roles of Fra-1 posttranslational modifications and transactivation mechanisms of select Fra-1 target genes. In addition to summarizing the Fra-1-dependent gene networks controlling proliferation, survival, and epithelial-mesenchymal transitions (EMT) in multiple cancer cell types, we highlight the roles played by Fra-1 in nonneoplastic cell populations recruited to the tumor microenvironment, and in mouse models of tumorigenesis. Next, we review the prognostic power of the Fra-1-associated gene signatures, and envisage potential strategies aimed at Fra-1 therapeutic inhibition. Finally, we discuss several recent reports showing the emerging roles of Fra-1 in the mechanisms of both resistance and addiction to targeted therapies.
Insights
The transcription factor Fra-1 (encoded by FOSL1) drives human tumor progression and metastasis. This review explores FOSL1
Area of Science:
- Oncology
- Molecular Biology
- Gene Regulation
Background:
- Fra-1 (FOSL1) is a key transcription factor in the AP-1 complex implicated in human cancer.
- Understanding Fra-1's role is critical for developing targeted cancer therapies.
Purpose of the Study:
- To provide a comprehensive review of the current knowledge on FOSL1 and its gene product, Fra-1.
- To discuss emerging topics, therapeutic strategies, and Fra-1's role in cancer progression and treatment resistance.
Main Methods:
- Literature review summarizing existing research on FOSL1.
- Analysis of transcriptional, epigenetic, and post-translational regulation of Fra-1.
- Examination of Fra-1's role in gene networks, tumor microenvironment, and therapeutic resistance.
Main Results:
- FOSL1 controls Fra-1 accumulation through transcriptional and epigenetic mechanisms in various solid tumors.
- Fra-1 influences proliferation, survival, epithelial-mesenchymal transitions (EMT), and the tumor microenvironment.
- Fra-1 signatures have prognostic value and Fra-1 is involved in resistance and addiction to targeted therapies.
Conclusions:
- Fra-1 is a significant driver of tumor progression, metastasis, and therapeutic resistance.
- Targeting FOSL1 presents a promising therapeutic avenue for various human cancers.
- Further research into Fra-1 regulation and function is warranted for effective cancer treatment strategies.
More Related Videos
Related Concept Videos
Abnormal Proliferation
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Mitogens and the Cell Cycle
Methods of Nuclear Reprogramming
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:

